The companies are now understood to be in advanced talks over a price of between $46.50 and $48 per share. City sources confirmed that the finishing touches were being put to a potential agreement.
They only had one drug and it failed.. does it matter what he says target is..lol
Their going to change the dose of steroids for final data, so very much still in the game and a potential game changer for patients.
Thats why this was $120 a day ago because it looks great.
Sentiment: Strong Buy
--- thanks to all---
Netflix to double its original programming in 2016
Original Programming Grants NFLX Full Global & Exclusive Rights
By : Andrew Tarantola
Original programming grants Netflix full exclusivity and global rights
why would they use CLVS at 28% when theres AZN at 60% rate response
Amicus Therapeutics, Inc. Sued for Securities Fraud In An Expanded Class Period
PR Newswire - 25 minutes ago
but good luck